Priorix (MMR vaccine) / GSK - LARVOL DELTA

Allergic Adverse Reactions Following Measles-Mumps-Rubella Vaccination in Children with Food Allergy: A Prospective Multicenter Study. (PubMed, Pediatr Allergy Immunol Pulmonol) - "Of the patients, 126 (62.4%) received Tresivac®, while 76 (37.6%) received Priorix®. It was determined that the cut-off values for cow's milk and egg white spIgE were found to be significant in identifying children at risk for allergic reactions following MMR vaccination. Children with food allergies who had a family history of atopy were found to have a higher risk of allergic reactions."

Clinical • Journal • Allergy • Cardiovascular • Dermatology • Food Hypersensitivity • Immunology • Infectious Disease • Measles • Mumps • Rubella • Urticaria

Implementing an MMR vaccination programme for adults living with HIV in response to a measles outbreak in London, UK (IAS-HIV 2025) - "We offered both the MMRVAXPRO and PRIORIX vaccines to provide an alternative for clients who declined porcine gelatine. Integrating measles immunity testing and MMR vaccination into routine HIV care is feasible. It ensures ease of access to vaccination and promotes vaccine uptake, improving health outcomes for people living with HIV."

Clinical • Human Immunodeficiency Virus • Infectious Disease • Measles • CD4

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=900 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Trial completion date: May 2027 ➔ Aug 2027 | Trial primary completion date: May 2027 ➔ Aug 2027

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

In brief: Prevention of measles. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Infectious Disease • Measles

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=900 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (clinicaltrials.gov) - P3 | N=1200 | Recruiting | Sponsor: Shanghai Institute Of Biological Products | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Infectious Disease • Measles • Mumps • Rubella

Persistence of Antibodies against Measles, Mumps, and Rubella after the Two-Dose MMR Vaccination: A 7-Year Follow-Up Study. (PubMed, Vaccines (Basel)) - P4 | "We followed a cohort of healthy children from a clinical trial (ClinicalTrials.gov NCT02408926) where they were administered either the Priorix vaccine (GlaxoSmithKline Biologicals, Rixensart, Belgium) or M-M-RII (Merck & Co., Kenilworth, NJ, USA) at 9 months and 2.5 years of age...Over the 4.5 years following the two-dose MMR vaccination, we observed a decline in the seroprotection rates against measles and mumps, but not rubella. Longitudinal monitoring of antibody persistence, among other strategies, will help predict population-level immunity and inform public health interventions to address potential future outbreaks."

Journal • Infectious Disease • Measles • Mumps • Rubella

Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (clinicaltrials.gov) - P3 | N=1200 | Not yet recruiting | Sponsor: Shanghai Institute Of Biological Products

Head-to-Head • New P3 trial • Infectious Disease • Measles • Mumps • Rubella

MET55: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (clinicaltrials.gov) - P3 | N=1328 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Jan 2023 | Trial primary completion date: Jul 2024 ➔ Jan 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Meningococcal Infections

MEQ00064: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (clinicaltrials.gov) - P3 | N=1528 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Meningococcal Infections • Pediatrics

MEQ00064: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (clinicaltrials.gov) - P3 | N=1528 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Meningococcal Infections • Pediatrics

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK's and Merck's measles-mumps-rubella (MMR) vaccines. (PubMed, Hum Vaccin Immunother) - "The other safety outcomes were similar between the GSK-MMR and Merck-MMR vaccines in both age groups. Hence, as recommended by the Advisory Committee on Immunization Practices, the GSK-MMR vaccine can also be used for routine immunization of children according to the current immunization schedule in the United States to prevent MMR."

Journal • CNS Disorders • Epilepsy • Infectious Disease

MET55: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (clinicaltrials.gov) - P3 | N=1482 | Recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Trial completion date: Sep 2023 ➔ Jul 2024 | Trial primary completion date: Sep 2023 ➔ Jul 2024

Trial completion date • Trial primary completion date • Infectious Disease • Meningococcal Infections

The Effects of Offering Freedom to Comply by Pediatricians and Nurses, Using the But-You-Are-Free (BYAF) Technique, on Vaccination Compliance on 185 Parents of Newborn Babies Conducted in Outpatient Clinics in Poland Between January 2022 and July 2022. (PubMed, Med Sci Monit) - "BACKGROUND This study aimed to evaluate, in outpatient clinics in Poland between January 2022 and July 2022, the effectiveness of the But-You-Are-Free (BYAF) social influence technique by healthcare professionals during interaction with 185 parents deciding about vaccinating (eg, Hexacima, Prevenor 13, Synflorix, Rotateq, Act Hib, Boostrix, Pentaxim, DTP, Imovax, Priorix, MMR, Tetracim, Adacel, Euvax B, Fuvax, FSME, Varilix, Nimenrix, Bexero vaccines) their babies. CONCLUSIONS The findings showed that participants who were exposed to the BYAF technique declared lower intentions to vaccinate their babies, and vaccinated them less often than those in the control condition. This result critically highlights that this technique should not be employed in the medical settings of pediatric vaccination."

Compliance • Journal • Pediatrics

Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. (PubMed, MMWR Morb Mortal Wkly Rep) - "Both PRIORIX and M-M-R II are fully interchangeable for all indications for which MMR vaccination is recommended. This report contains ACIP recommendations specific to PRIORIX and supplements the existing ACIP recommendations for MMR use (1,2)."

Journal • Infectious Disease

Similar Low Rate of Febrile Convulsions and Comparable Safety Data Reported for Gsk’s Measles-mumps-rubella (MMR) Vaccine versus Merck’s MMR Vaccine in Clinical Trials (AAP-NCE 2022) - "The FC rates were low and evenly distributed between GSK-MMR and M-M-R II vaccine groups. The rates of FC between 7–10 days post-vaccination were consistent with the rates reported for both vaccines in the literature, and no specific pattern of FC was identified. Overall, the safety of GSK-MMR vaccine did not differ from the known safety profile of M-M-R II vaccine."

Clinical • CNS Disorders • Epilepsy • Infectious Disease

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Hepatology • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Meningococcal Infections • Pneumococcal Infections • Respiratory Diseases • Tetanus • Varicella Zoster

Expanded table: Some vaccines for adults. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Hepatology • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Meningococcal Infections • Pertussis • Respiratory Diseases • Tetanus • Varicella Zoster

"$GSK GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older https://t.co/oLNR9j0l6W #fdaapproval" (@stock_titan)

FDA event • Infectious Disease

A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella. (PubMed, Mol Ther Oncolytics) - "In addition, PeptiENV therapy, in combination with immune checkpoint inhibitor therapy, improved tumor growth control and survival as well as increased the number of mice responsive to immune checkpoint inhibitor therapy. Importantly, mice pre-vaccinated with the MMR vaccine responded equally well, if not better, to the PeptiENV therapy, indicating that pre-existing immunity against the MMR vaccine viruses does not compromise the use of this novel cancer vaccine platform."

Journal • Immune Modulation • Infectious Disease • Inflammation • Melanoma • Oncology • Solid Tumor